

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/206928 A1

(51) International Patent Classification:

C07K 14/47 (2006.01) C12N 15/861 (2006.01)
C07K 14/005 (2006.01)

(21) International Application Number:

PCT/US2024/022377

(22) International Filing Date:

29 March 2024 (29.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/455,867 30 March 2023 (30.03.2023) US

(71) Applicant: **PHARMA CINQ, LLC** [US/US]; 1601 Research Boulevard, Rockville, Maryland 20850 (US).

(72) Inventors: **LUO, Tianci**; 7229 Preservation Court, Fulton, Maryland 20759 (US). **LIPUT, Daniel**; 3404 St. Theresa Ct., Olney, Maryland 20832 (US). **LIANG, Fong Qi**; 13504 W. Oak Ct., Mount Airy, Maryland 21771 (US).

(74) Agent: **BOUCHEZ, Cynthia M.**; 8201 Greensboro Drive, Suite 1060, McLean, Virginia 22102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE

(57) Abstract: The present invention relates to nucleic acids coding for and capable of expressing a full-length rod-derived cone viability factor (RdCVF) and human IgK signal sequence and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting a full-length RdCVF and human IgK signal sequence, and methods of treatment.



WO 2024/206928 A1